Levofloxacino Pharma Combix (Levofloxacin)

Levofloxacin exerts its antibacterial effect by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are essential for DNA supercoiling, replication, and transcription. Inhibition of these targets prevents the unwinding and resealing of DNA strands, leading to halted bacterial DNA synthesis and ultimately bacterial cell death.

The dosage of Levofloxacino Pharma Combix is individualized by the prescriber according to the infection type, severity, patient age, renal function and other clinical factors. Only a qualified healthcare professional can determine the appropriate dose and treatment duration for each patient.

Levofloxacino Pharma Combix is classified as a prescription‑only medication, and its safety in pregnancy or lactation has not been definitively established. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Levofloxacin offers broad‑spectrum coverage against many Gram‑positive and Gram‑negative bacteria, often with once‑daily dosing, which can be advantageous over some beta‑lactams that require multiple daily doses. However, its fluoroquinolone class carries specific safety considerations, such as tendon toxicity and QT prolongation, which may make other classes preferable in certain patient populations.

Levofloxacino Pharma Combix should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keeping the product in a dry, well‑ventilated area helps maintain its stability and potency throughout its shelf life.

Levofloxacino Pharma Combix is supplied as an oral dosage form. The tablets or capsules are taken by mouth with or without food, as directed by the prescribing clinician. Patients should swallow the medication whole and follow any specific instructions regarding timing relative to meals or other medicines.

Serious adverse events linked to levofloxacin include tendon rupture (particularly of the Achilles tendon), QT interval prolongation leading to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, hepatic injury, and peripheral neuropathy. Patients should be advised to seek immediate medical attention if they experience sudden tendon pain, palpitations, severe rash or gastrointestinal symptoms.

Levofloxacino Pharma Combix is contraindicated in individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any of the product’s excipients. It should also be avoided in patients with a history of tendon disorders related to fluoroquinolone use, uncontrolled cardiac arrhythmias, or those taking medications that significantly prolong the QT interval without careful monitoring.